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SUMMARY 
 
This study is a six year retrospective review of the histopathology of nasopharyngeal 
masses in adult patients who underwent a biopsy in theatre at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) from 1st January 2003 to 31st December 2008. 
 
Eighty one patients were included in this study. They comprised of 54 males (67%) and 27 
females (33%) aged between 18 and 82 years. There was no statistical difference between 
the two genders in terms of their ages (p= 0.39). 
 
Fifty two patients (64%) had benign disease and 29 patients (36%) had malignant disease 
(ratio 1.8:1). Thirty four males (65%) and 18 females (35%) had benign disease. Twenty 
males and 9 females had malignant disease. There was no significant correlation between 
gender and malignancy (r= -0.04, p=0.75). 
 
The independent predictors of the nature of the tumour were: nasal congestion, epistaxis, 
hearing loss, otalgia and Human Immunodeficiency Virus (HIV) status. The statistically 
significant positive predictors of malignancy were the presence of nasal congestion, 
epistaxis and otalgia. The presence of at least one or more of these symptoms was 
associated with an odds ratio of 3.06 for malignant disease. (CI= 1.17-8.01). The presence 
of hearing loss was independently associated with benign disease (p=0.031). 
 
The HIV status was known in 41 of the 81 patients. Of the 41 patients whose HIV status 
was known, 25 were male and 16 were female. The HIV positive patients comprised of 19 
males (76% of all males) and 9 females (56% of all females).  
 
 
 xii
The presence of HIV infection was independently associated with benign disease. The 
absence of HIV infection was in fact associated with malignant disease, with an odds ratio 
of 4.00 and 95% confidence intervals of 1.04 to 15.43.  
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CHAPTER 1 
 
1.  INTRODUCTION 
Analyses of tumour types of the nasopharynx are poorly researched across the globe and 
this scenario is also applicable to South Africa. Majority of the research pertaining to 
tumours of the nasopharynx focuses specifically on the nasopharyngeal carcinoma (NPC), 
which is endemic to certain parts of the world. In most Western countries and also in South 
Africa, nasopharyngeal carcinoma accounts for less than two percent of all head and neck 
tumours (Larson, Clifford & Einhorn, et al., 1976; Glynn, Keogh & Ali, et al., 2006). 
There has not been any historical study in South Africa describing the prevalence or 
incidence of the various nasopharyngeal pathologies in adults. 
 
South Africa has one of the highest prevalence rates of Human Immunodeficiency Virus 
(HIV) infection in the world (10.6%), with 5.21 million people known to be living with 
this infection (Statistics South Africa, 2009). Since the onset of the HIV epidemic, 
Otorhinolaryngologists have been recognising at a clinical level, a changing spectrum of 
diseases occurring in the nasopharynx.   
 
1.1  MOTIVATION FOR THE STUDY 
The decision to conduct this study was prompted by the need to identify the prevalence of 
benign nasopharyngeal pathology in a South African setting in comparison to their 
malignant counterparts. The potential influence of HIV infection on these tumours would 
also be determined. 
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If the results of this study prove significant, it could potentially influence the future 
management of these tumours by specifying whether all nasopharyngeal tumours need to 
be biopsied. 
 
1.2 OBJECTIVES 
 
The objectives of this study were: 
 
1. To determine the frequency of the various nasopharyngeal tumours presenting to 
the Otorhinolaryngology department at the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH), formerly known as Johannesburg General Hospital. 
 
2. To determine if there was an association between the presenting symptoms of 
nasopharyngeal disease and a tumour type (i.e. benign or malignant). 
 
3. To determine if there was an association between nasopharyngeal neoplasms and 
the presence of a superimposed HIV infection. 
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CHAPTER 2 
 
2.  LITERATURE REVIEW 
This chapter gives a brief description of the anatomy of the nasopharynx, discussion on the 
symptoms related to nasopharyngeal disease, classification of nasopharyngeal tumours and 
summary of the well documented NPC. A discussion on the clinical and radiological 
evaluation of the nasopharynx is provided along with a superficial overview of the burden 
of HIV in South Africa and pathology in the head and neck. Focus has been placed on 
nasopharyngeal pathology related to HIV infection. This chapter concludes with the 
observations and hypothesis of this study. 
 
2.1  ANATOMY 
2.1.1 Embryology 
The nasopharynx is mainly derived from the primitive foregut (endoderm) and is separated 
from the primitive buccal cavity (ectoderm) by the buccopharyngeal membrane. The 
buccopharyngeal membrane eventually disappears and leaves the primitive pharynx and 
buccal cavity in communication with each other. The two main outpouchings from this 
developing nasopharynx is Rathke’s pouch (ectoderm) and the Eustachian tube and middle 
ear (endoderm). Different tissue types exist in the nasopharynx and it is important to know 
where the tissues originate. These tissues migrate and nests of tissue can be left behind in 
their migration path and present with varying pathology of endoderm, ectoderm and 
mesoderm (Godtfredson, 1944). 
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2.1.2 Surgical Anatomy 
The nasopharynx is a complex anatomical area, bounded by various bony, muscular, 
vascular and neural structures. It is the uppermost part of the pharynx, lying behind the soft 
palate and communicates anteriorly with the nasal cavity through two large apertures 
called the posterior choanae. It extends superiorly, from the base of the skull, forming a 
continuous surface that lies inferior to the body of the sphenoid and the basilar part of the 
occipital bone. The floor of the nasopharynx is formed by the superior surface of the soft 
palate.  
 
The lateral aspect of the nasopharynx is defined by the temporal bones. The pharyngeal 
orifice of the Eustachian tubes lies in the lateral wall of the nasopharynx, where it is bound 
by a tubal elevation or torus, produced by the medial end of the cartilaginous part of the 
Eustachian tube. Extending inferiorly from the torus is the salpingo-pharyngeal fold, which 
houses the salpingo-pharyngeus muscle responsible for the opening of the Eustachian tube 
during swallowing. Posterior to the torus and the salpingo-pharyngeal fold is a slit like 
lateral projection called the pharyngeal recess or the fossa of Rosenmuller.  
 
2.1.3 Micro-anatomy 
The mucosa of the nasopharynx is predominantly a non-keratinizing squamous epithelium. 
The anterior wall of the roof of the nasopharynx is, however, lined by moist ciliated 
respiratory epithelium. The transition area of the mucosa varies from respiratory to 
squamous type and can be gradual or abrupt with islands of tissue mixed with each other. 
This is especially prevalent in the area of the pharyngeal recess, making this transitional 
zone an ‘unstable’ one and thus an area favourable for the development of tumours or 
malignancies.  
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The submucosa of the nasopharynx has a very rich supply of blood vessels, lymphatic 
channels, sero-mucinous glands, minor salivary glands, nerve plexuses and a variety of 
connective tissues. This diversity of tissues allows for a multitude of neoplastic diseases 
that do arise in the nasopharynx (Cummings, Flint & Harker, et al., 2005). 
 
 
Figure 1: Sagittal section of the nasopharynx and nasal cavity (Encyclopaedia 
Britannica, 2003) 
By courtesy of Encyclopaedia Britannica, Inc., copyright 2003; used with permission. 
Image available at: http://www.britannica.com/EBchecked/topic-art/22980/68641/Sagittal-
section-of-the-pharynx. 
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2.2  CLASSIFICATION OF NASOPHARYNGEAL TUMOURS 
Neoplastic growths of the nasopharynx include benign and malignant pathologies and 
these are classified into the epithelial and the non-epithelial groups.  
 
Common benign conditions include angiofibroma, allergic-type polyps, squamous 
papillomata, pleomorphic adenomas, schwannoma and teratomas.  
 
Malignant lesions of the nasopharynx include nasopharyngeal carcinoma, adenocarcinoma, 
adenoid cystic carcinoma, lymphomas, sarcomas, malignant melanoma, plasmacytoma, 
chondrosarcoma and rhabdomyosarcoma.  
 
Tumours of the nasopharynx needs to be differentiated from tumours in the nasal cavity 
due to the diverse pathology in this area and thus needs its own classification (Heffner, 
1990). The histological classification of nasopharyngeal tumours was developed by the 
World Health Organization (WHO) in 1978, and revised in 1991 (Shanmugaratnam & 
Sobin, 1993) (see table 1). 
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Table 1: WHO Histological Classification of Tumours of the Nasopharynx-1991. 
 Benign Malignant 
1. Epithelial Tumours Papillomata Nasopharyngeal carcinoma  
 Pleomorphic adenoma Squamous cell carcinoma (keratinizing carcinoma) 
Oncocytoma Non-keratinizing carcinoma 
Basal cell adenoma 1. Differentiated non-keratinizing carcinoma  
Ectopic pituitary adenoma 2. Undifferentiated carcinoma (of nasopharyngeal type) 
 
Adenocarcinoma 
Papillary adenocarcinoma 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Polymorphous low grade 
adenocarcinoma 
2. Soft Tissue Tumours Juvenile angiofibroma Fibrosarcoma 
 Haemangioma Rhabdomyosarcoma 
Haemangiopericytoma Angiosarcoma 
Neurilemmoma 
(Schwannoma) Kaposi sarcoma 
Neurofibroma Malignant haemangiopericytoma 
 
Malignant nerve sheath 
tumour 
Synovial sarcoma 
3. Tumours of Bone and 
Cartilage   
4. Malignant lymphomas  Non Hodgkin’s lymphoma 
 
 
Extramedullary Plasmacytoma
Midline malignant reticulosis 
Histiocytic lymphoma 
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 Benign Malignant 
Hodgkin’s disease 
5. Miscellaneous Tumours Meningioma Malignant melanoma 
 Craniopharyngioma Chordoma 
Mature teratoma Malignant germ cell tumour 
6. Secondary Tumours   
7. Unclassified Tumours   
8. Tumour like Lesions Cysts  
 Heterotopic pituitary tissue
 
Meningocele,  
Meningo-encephalocele 
Fibro-inflammatory 
pseudotumour 
Infective granulomas 
Wegener's granulomatosis 
Pseudoepitheliomatous 
hyperplasia 
Oncocytic metaplasia and 
hyperplasia 
Pyogenic granuloma 
Lymphoid hyperplasia 
Malakoplakia 
Amyloid deposits 
 
 
 
 
 9
2.3  SYMPTOMATOLOGY OF NASOPHARYNGEAL DISEASE 
 
The general symptoms of nasopharyngeal mass lesions include nasal obstruction, epistaxis, 
hearing loss, otalgia and Eustachian tube obstruction (Hopping, Keller & Goodman et al., 
1983; van Hasselt & Gibb, 1991). It must however be noted that infiltrative diseases may 
present with neurological deficits and cervical lymphadenopathy (Godtfredson, 1944; 
Glynn, et al., 2006).  
 
Mass lesions arising in the nasopharynx generally cause obstruction to the passage of nasal 
air flow, usually in the posterior choanae, thus resulting in the nasal obstructive symptoms. 
With further growth, nasopharyngeal tumours can also extend anteriorly into the nasal 
cavity and present as a mass protruding through the nostrils. Commonly associated 
symptoms include nasal blockage, anosmia, nasal discharge and intermittent epistaxis. If 
the mass extends inferiorly, it can present as a mass in the oropharynx which pushes the 
soft palate forward. Typical presentation thereof would include snoring or stertor and a 
hypo nasal quality of speech. 
 
Masses in the nasopharynx can obstruct the pharyngeal opening of the Eustachian tube. 
This results in accumulation of secretions produced by the respiratory mucosa in the 
middle ear and ultimately middle ear effusions.  Patients can experience otalgia from 
distension of the tympanic membrane. Chronic middle ear effusions can be associated with 
a temporary or permanent hearing loss and this is usually conductive in nature.  
 
The nasopharynx has a rich network of lymphoid tissue and lymphatic channels. The main 
drainage site of the nasopharyngeal lymphatics is to the retropharyngeal lymph nodes, and 
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subsequently, the upper posterior triangle and the deep cervical lymph nodes. Lesions that 
extend out of the nasopharynx can result in lymphadenopathy in the drainage areas of the 
surrounding structures. Metastatic disease involving lymph nodes in the upper deep 
cervical area and the posterior triangle can thus be an early presentation of nasopharyngeal 
pathology. 
 
The nasopharynx is in close proximity to the sphenoid and orbital bones, the cavernous 
sinus and brain. Tumour spreading and infiltrating into these adjacent areas cause 
neurological deficits and cranial nerve fallout, especially the lower cranial nerves, and 
cavernous sinus thrombophlebitis. The common cranial nerve deficits include: 
ophthalmoplegia or diplopia, headaches, trigeminal neuralgia, hoarseness and tongue and 
pharyngeal paralysis (Godtfredson, 1944). 
 
The nasopharynx thus provides easy access to its adjacent anatomical structures, thus 
clinical presentation of neoplasia will vary according to the sites of involvement.  
 
Figure 2: Patient with NHL of the nasopharynx with significant lymphadenopathy. 
Lymph nodes 
in the upper 
deep cervical 
chain and 
posterior 
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2.4  NASOPHARYNGEAL CARCINOMA (NPC) 
 
The most widely researched malignant nasopharyngeal lesion is NPC. In Western 
countries, NPC accounts for less than one percent of all malignant tumours (Stein, Ruff & 
Weaving, et al., 1996; Johannsson, Sveinsson & Agnarsson, et al.,1997; Her, 2001; Glynn, 
et al., 2006) but in countries in the East especially those with a high Chinese population, 
the incidence ranges from 13-21% (Glynn, et al 2006). In certain areas such as North East 
Africa, Southern China and Southeast Asia, NPC is regarded as being endemic.  
 
Genetic, environmental and dietary factors and Epstein Barr virus (EBV) infection are 
implicated as the causative factors of NPC (van Hasselt, et al., 1991; Her, 2001; Chan, Teo 
& Johnson, 2002). Human leukocyte antigens (HLA) haplotypes are genetic factors that 
pose a risk for malignancy and some of these are well associated with NPC (van Hasselt, et 
al., 1991; Her, 2001; Chan, et al., 2002). This could account for the continued higher 
prevalence of NPC in people of Chinese origin that have emigrated to Western countries 
than their Eastern counterparts (Tse,Yu & Mang, et al., 2006).  
 
The consumption of salted fish and other foods containing high levels of nitrosamines, 
which is thought to be carcinogenic, together with vitamin deficiencies, poses a substantial 
risk for development of NPC (Her, 2001). Tobacco smoking, formaldehyde, hydrocarbons, 
incense burning and dust exposure are also considered as significant environmental risk 
factors for the development of NPC.  
 
Nasopharyngeal carcinoma seems to develop with gradual changes in the histology of the 
mucosa (Chan, et al., 2002). The tumour begins as patchy dysplasia and it is suggested that 
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environmental carcinogens may be responsible (Chan, et al., 2002). These changes affect 
the chromosomes and results in inactivation of tumour suppressor genes. EBV infection 
seems to be the crucial factor that leads to severe dysplasia. It is thought to contain genes 
that are capable of transforming human epithelial cells. In areas that are endemic for NPC, 
EBV antibody titres are particularly high. Monitoring EBV-DNA levels in plasma is a 
valuable tool for prognosticating the cancer, assessing responses during treatment and 
monitoring for recurrence (Her, 2001; Chan, et al., 2002; Cummings, et al., 2005). 
 
There are many classifications of NPC based on the histological findings but the most 
recent and widely accepted classification is the WHO 1991 histological classification 
(Shanmugaratnam, et al., 1993) (see table 2). Categorising NPC according to histological 
types may prognosticate response to treatment (Chan, et al., 2002; Goh & Lim, 2009). 
 
Table 2: The WHO 1991 Classification of NPC 
I – Keratinising squamous cell carcinoma II- Non-keratinising carcinoma 
  A) Undifferentiated 
 B) Differentiated 
 
 In 1997, a new International Union Against Cancer (UICC) / American Joint Cancer 
Committee (AJCC) stage classification was formulated (see tables 3 &4). This new staging 
considered whether the tumour extended to areas associated with a higher metastatic rate 
(e.g. the parapharyngeal space), intracranial extension and nodal involvement and taking 
these factors into consideration, seems to prognosticate NPC more accurately (Chan, et al., 
2002). 
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Table 3: UICC/AJCC 1997 TNM Classification of NPC 
T (Tumour) N (Regional nodal 
involvement) 
M (Metastasis) 
T1 - Nasopharynx N1- Unilateral nodal 
involvement of < 6cm in the 
greatest dimension, above 
the supraclavicular fossae 
M0 - No distant metastasis 
T2 - Soft tissue of 
oropharynx and/or nasal 
fossa 
N2- Bilateral nodal 
involvement of < 6cm in the 
greatest dimension, above 
the supraclavicular fossae 
M1 - With distant metastasis
T2a-Without 
Parapharyngeal extension 
N3- Metastasis in the lymph 
nodes > 6cm, in the 
supraclavicular fossa 
 
T2b- With Parapharyngeal 
extension 
  
T3 - Invades bony structures 
and/or paranasal sinuses 
  
T4 - Intracranial extension, 
involvement of cranial 
nerves, infratemporal fossa,    
hypopharynx or orbit 
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Table 4: UICC/AJCC 1997 Staging of NPC 
 
Stages   
Stage 0    T in situ N0 M0  
Stage 1   T1 N0 M0 
Stage 2a   T2a N0 M0 
Stage 2b   T2b N0 M0 
       T1 N1 M0 or T2 N1 M0 
Stage 3    T3 N0, N1 M0 
     T1, 2, 3 N2 M0 
Stage 4a   T4 N0, N1, N2 M0 
Stage 4b   Any T, N3 M0 
Stage 4c   Any T, Any N, M1 
 
Nasopharyngeal carcinoma, even in advanced stages, has good cure rates. Initial treatment 
in the 1990’s, involved radical radiotherapy (60-70Gy) being delivered in two dimensions, 
however subsequent technological advances allowed radiation to be delivered in three 
dimension conformal (3DCRT) or intensity-modulated (IMRT) techniques. The 3DRT and 
IMRT methods proved to be superior to the older treatment, improving local cure rates 
from 90% compared to the 80% achieved by two dimensional radiotherapy technique 
(Chan, et al., 2002; Goh, et al., 2009). These new modalities combined with images from 
CT scans and MRI, help determine the gross tumour volume to be treated, allowing 
radiation to be delivered to the tumour-filled areas whilst sparing vital structures in the 
vicinity. It is now also possible to use altered fractionation and dose escalation techniques 
by intracavity brachytherapy, and this could lead to better results associated with local 
control of the disease (Chan, et al., 2002). 
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Combined chemo-radiation was proven in 1998 to have a significant advantage over 
radiotherapy alone (Her, 2001; Chan, et al., 2002) and this resulted in the change of 
treatment protocol for these tumours. Concurrent chemo-radiation is beneficial for 
advanced, local or regional tumours as well as for treatment of recurrent disease. 
 
Nasopharyngeal carcinoma is a very chemo sensitive tumour and the use of platinum based 
cytotoxic agents such as Cisplatin or Carboplatin, and combined with 5-fluorouracil, 
bleomycin, gemcitabine, paclitaxel or ifosfamide allows the tumour to be more 
radiosensitive, thus producing good response rates (Stein, et al., 1996; Chan, et al., 2002). 
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2.5  CLINICAL EVALUATION OF THE NASOPHARYNX 
 
Examination of the nasopharynx can either be performed in an outpatient department 
(OPD) or clinic setting, or in a theatre utilising the following examination methods, viz.: 
mirror examination, rigid endoscopy or flexible endoscopy.  
 
Mirror examinations can be easily performed on a conscious patient with the patient seated 
in front of the examiner who is equipped with a head lamp and a nasopharyngeal mirror. 
The mirror is warmed to prevent misting and the oropharynx can be anaesthetised with 
topical agents to reduce the gag effect. The mirror is placed just behind the soft palate 
facing upwards to view the nasopharynx. The disadvantage of this procedure however, is 
that it may only give a limited view of the fossa of Rosenmuller and may also induce the 
gag effect. In theatre, examination of the nasopharynx using the mirror is aided by using a 
mouth gag to keep the oral cavity opened and the soft palate is retracted using the Jacques 
rubber catheters. Biopsies can then be taken transorally. 
 
Rigid endoscopy refers to using zero or thirty degree Hopkins rod endoscopes (telescopes) 
to visualise the nasopharynx. In a similar method as described above, the patient is seated 
in front of the examiner. The nasal cavity can be anaesthetised with a topical agent and the 
scope is advanced into and through the nasal passage until it reaches the nasopharynx. 
Visualisation of the nasopharynx with this method is of a better quality than mirror 
examination but anatomical variations especially of the nasal septum can make it difficult 
to manoeuvre these scopes to reach the nasopharynx. If a biopsy is to be taken, the biopsy 
forceps is passed through the nostril (on the side of the pathology) and the scope is passed 
through the nostril on the unaffected side and the biopsy can be performed under direct 
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vision. An alternative technique described by van Hasselt (1991) makes use of a ninety 
degree Hopkins rod passed transorally and may be used with palatal retractors. This 
provides excellent views of the nasopharynx picking up even the smallest of tumours. 
 
The introduction of the fibre optic flexible nasopharyngoscope has simplified the 
examination of patients in the OPD or clinic setting. Built with a biopsy port, this scope 
allows for the convenient examination of the nasopharynx and concurrent biopsy without 
needing to take a patient to theatre for the procedure.  The risks of the biopsy include 
patient discomfort hence poor co-operation, and associated bleeding. Flexible endoscopy 
provides a panoramic view of the nasopharynx and even tiny lesions can be identified.  
 
Outpatient based biopsy of the nasopharynx is not generally recommended although this 
procedure may be particularly appropriate for patients that are too ill to undergo a general 
anaesthesia (Glynn, et al., 2006).  
 
The clinical appearance of a nasopharyngeal mass may be a vital clue to predict if a tumour 
is benign or malignant. Smooth, symmetric, non-ulcerated masses that do not involve the 
fossa of Rosenmuller, are most likely to be benign (Barzan, Carbone & Tirelli, et al., 1990; 
Glynn, et al., 2006). Ulcerated and irregular looking masses however, are most likely to be 
malignant. Some tumours may also extend submucosally and the nasopharynx may appear 
normal on flexible endoscopy, so malignancy can be missed. If it is decided that a biopsy 
of a normal looking nasopharynx in patients with nasopharyngeal symptomatology is not 
warranted, close outpatient follow up is strongly recommended. 
 
 
 18
As tumours in the nasopharynx grow, they may extend into the nasal passages and present 
as a mass in the anterior nasal passages. Hence, biopsies of nasal lesions may in fact be 
masses originating from the nasopharynx.  
 
In patients with occult primary tumours, a panendoscopy is performed, taking random 
biopsies from areas that are highly probable to harbour malignancies. Panendoscopy refers 
to endoscopic examination of the nasopharynx (especially in the region of the fossa of 
Rosenmuller), oral cavity, oropharynx, hypopharynx, larynx, trachea, bronchi and upper 
oesophagus. 
 
 
 
 
 
 
 
 
 
 
Figure 3: View of the nasopharynx through a rigid scope (McClay, 2008). 
Image reprinted with permission from eMedicine.com, 2010. Available at:  
http://emedicine.medscape.com/article/872216-overview.  
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2.6  RADIOLOGICAL EVALUATION OF THE NASOPHARYNX 
 
The radiological evaluation of the nasopharynx is done using plain X-rays, Computerised 
tomography (CT) scans and Magnetic resonance imaging (MRI), with or without the use of 
contrast and angiography.  
 
The nasopharynx can be easily seen on a lateral X-ray view and the presence of increased 
soft tissue in the area behind the nasal cavity is suggestive of mass lesions in the 
nasopharynx. The X-ray may also demonstrate surrounding bony erosion. 
 
 
Figure 4: Lateral X-ray view of the nasopharynx. 
 
CT scans are especially useful for evaluation of the bony framework of the nasopharynx. 
Erosion of this bony framework warns the surgeon of mass extension and infiltration into 
the surrounding structures and possibly into the brain. Other useful sites to assess on CT 
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scans are extension of tumour into the parapharyngeal space and the pterygoid muscles 
(Sievers, Grees & Baum, et al., 2000). 
 
 
Figure 5: CT- Axial cut through a normal nasopharynx. 
 
There are four important fascial sheaths in the nasopharynx, viz. pharyngobasilar, 
buccopharyngeal, carotid and prevertebral sheaths. These fascial planes can be identified 
on CT scans and the associated pattern of tumour spread within or across the planes, can 
assist with the prediction on whether a lesion of the nasopharynx is benign or malignant 
(Bohman, Mancuso & Thompson, et al., 1981). Benign mucosal lesions will generally not 
cross the dense pharyngobasilar layer, and the loose buccopharyngeal layer allows benign 
tumours to assume a spherical configuration. Malignant lesions, on the other hand, easily 
Eustachian 
Tube 
Fossa of 
Rosenmuller 
Torus 
tubaris 
 
 
 21
invade the pharyngobasilar fascia and do not stay confined to the fascial planes (Bohman, 
et al, 1981). 
 
 
Figure 6: CT- Axial cut showing a malignant nasopharyngeal tumour. 
 
Figure 7: CT- Axial cut through the nasopharynx showing a benign tumour. 
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Magnetic resonance imaging is the radiological investigation of choice for the nasopharynx 
(Sievers, et al., 2000; Goh, et al., 2009). It has a vastly superior soft tissue contrast and 
resolution making it the investigation of choice to assess perineural spread, involvement of 
the parapharyngeal space and other surrounding areas of the nasopharynx such as the 
orbits, sinuses and infratemporal fossa. T1 weighted images, although it does not delineate 
tumour from muscle well, is very useful for the assessment of the parapharyngeal space. 
When used with gadolinium, the tumour becomes distinguishable from muscle and fat 
(Sievers, et al., 2000). Magnetic resonance imaging is essential if there is any suspicion of 
intracranial extension. The combination of T1 weighted imaging, T2 weighted imaging 
with gadolinium and fat saturation sequences makes delineation of tissues easy and reliable 
(Sievers, et al., 2000).   
 
 
Figure 8: MRI sagittal section showing a mass in the nasopharynx. 
Nasopharyngeal 
mass 
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A Positron emission tomography (PET) scan utilising 2-[fluorine-18] fluoro-2-deoxy-d-
glucose (FDG) is a useful diagnostic tool for identifying malignancies, staging of the 
disease and detecting any recurrence of malignancy (Blodgett, Fukui & Snyderman, et al., 
2005). Used alone, PET scans have a low specificity of tumour detection due to lack of 
anatomical landmarks and variable uptake of FDG. Positron emission tomography 
combined with CT scanning allows better localization of FGD uptake and can more 
accurately identify areas of malignancy and recurrence of tumour (Fukui, Blodgett & 
Snyderman, et al., 2005; Goh, et al., 2009). Of all of the above radiological modalities, 
FDG-PET is the most accurate for local residual or recurrent NPC (Lui, Xu & Yang, et al., 
2007). 
 
The combination of all the above-mentioned radiological investigations of the nasopharynx 
and its’ surrounding areas is essential for accurate staging of the disease and based on these 
investigations, appropriate management decisions can be made.  
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Figure 9: PET-CT of the nasopharynx . 
The pictures above show asymmetry in the left side of the nasopharynx and there is 
increased uptake of FDG in this area which indicates residual disease in this patient. 
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2.7  THE BURDEN OF HIV IN SOUTH AFRICA 
 
Global statistics in 2007 showed that there were 33.2 million people living with HIV. Of 
these, 30.8 million were adults and 2.5 million were children under fifteen years of age. 
Two and a half million people were newly infected with HIV in 2007, comprising of 2.1 
million adults and 420000 children less than 15 years. Approximately 1.7 million adult 
deaths in 2007 were attributed to AIDS. In 2007, Southern Africa accounted for 32% of all 
people living with HIV and almost one third of all new HIV infections and AIDS deaths 
globally. South Africa was reported to have the highest number of HIV infection in the 
world. (UNAIDS, 2007).  
 
The South African population was estimated to be around 49 million people in July 2009. 
The prevalence of HIV infection was estimated to be 10.6% and the number of people 
living with HIV was 5.21 million. Adults between 15 to 49 years of age accounted for 17% 
of this number. Over the years HIV prevalence rates have slowly risen from 9.3% in 2001 
to 10.6% in 2009 and there are over 1 million more people living with HIV in 2009 as 
compared to 2001(4.1 million). (Statistics South Africa, 2009).  
 
South Africa has the biggest anti-retroviral (ARV) programme in the world, but having the 
highest prevalence of HIV in the world, the access to treatment is still far too low (Leake, 
2009). The international recommendations for starting ARV’s, is at a CD4 level of below 
350 cells/mm2, however in South Africa, the starting level is a CD4 level of below 
200cells/mm2. By the time these patients receive their treatment, the disease has usually 
progressed further (Leake, 2009). It is estimated that there were 568 000 people receiving 
ARV’s in the public sector by mid 2008 (Adam & Johnson, 2009). The number of people 
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in need of ARV’s is over 1.5 million and the estimated costs of full scale ARV programme 
for 2008/9 was 996 million US dollars (Palitza, 2006). 
 
A successful ARV programme needs support and commitment. The South African 
government has acknowledged that ARV treatment is a priority and has committed to 
supporting and expanding the current ARV programme (Kilfe, 2009). Also, with the US 
providing a further 900 million US dollars for ARV treatment over the next two years over 
and above the 4.2 billion dollars that was budgeted for ARV’s in 2010, access to ARV’s 
will be easier and the South African government’s estimated target coverage of ARV 
treatment is a possibility (US to commit R900mil for ARVs in South Africa, 2009). 
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2.8  HIV AND THE OTORHINOLARYNGOLOGIST 
 
In light of the current HIV epidemic, the Otorhinolaryngologist is faced with the challenge 
of diagnosing diseases associated with HIV infection. This is due to the fact that it is 
estimated that approximately 40% to 60% (Barzan, et al., 1990) of all patients with HIV 
will at some point present with head and neck manifestations of HIV infection (Gurney & 
Murr, 2003). More recent studies (Moazzez & Alvi, 1998) suggest that nearly 100 % of 
patients with AIDS will have head and neck manifestations of this disease.  
 
Pathology in the head and neck related to HIV includes oropharyngeal, laryngeal, nasal 
cavity, otological, cutaneous, parotid and lymphatic lesions (Moazzez, et al., 1998) (see 
table 5). The nasopharynx is of critical importance to this study in that it may harbour 
growths such as Kaposi sarcoma (KS) or Non- Hodgkin’s lymphoma (NHL) both of which 
are AIDS defining or stage four of the HIV infection (Mohammed, 2007). The most 
common benign lesion in the nasopharynx in the presence of HIV infection is benign 
lymphoid hyperplasia. 
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Table 5: Head and Neck Manifestations of HIV 
Oral Nasal Cutaneous Otological Neck 
Oral ulceration Sinusitis Kaposi sarcoma Otitis externa Lymphadenopathy
Candidiasis Allergic rhinitis Bacillary 
angiomatosis 
Serous otitis 
media 
Parotidomegaly 
Hairy leukoplakia Nasopharyngeal 
lymphoid 
hyperplasia 
Seborrheic 
dermatitis 
Eustachian tube 
dysfunction 
Neck space 
infections 
Herpes simplex Kaposi sarcoma Herpes zoster Hearing loss  
Kaposi sarcoma Non-Hodgkins 
lymphoma 
Skin infections   
Non-Hodgkin’s 
lymphoma 
 Cutaneous 
carcinomas 
  
Squamous 
carcinoma 
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2.9  HIV AND THE NASOPHARYNX 
 
A variety of diseases are present in the nasopharynx of the HIV positive population. 
Bacterial and protozoal infections as well as tuberculosis have been identified. Mass 
lesions of the nasopharynx include both benign and malignant disease. 
 
The most common benign nasopharyngeal lesion in HIV positive patients is benign 
lymphoid hyperplasia (Barzan, et al., 1990). Benign lymphoid hyperplasia is also referred 
to as nasopharyngeal lymphatic tissue hypertrophy (NLTH). In a case series involving 
seven patients (Stern, Lin & Lucente, 1990) none with noticeable features of HIV 
infection, all presented with nasal obstruction and hearing loss. Only six of these patients 
had otitis media effusions. Examination of the nasopharynx revealed large nasopharyngeal 
masses which on biopsy, revealed histological diagnoses of benign lymphoid hyperplasia. 
Serological testing for HIV infection found that all of these patients were HIV infected.  
 
A prospective study (Barzan, et al., 1990) was conducted on 218 HIV negative patients and 
59 HIV positive patients comparing the nasopharyngeal lymphatic tissue of both groups. It 
was noticed that the macroscopic appearance of nasopharyngeal lymphatic tissue 
hyperplasia (NLTH) was always smooth, symmetrical and never ulcerated. It was however 
observed that NLTH was far more common in the HIV positive group. Based on these 
findings, the authors suggested that NLTH be recognised as one of the most common head 
and neck manifestations of HIV. 
 
Nasopharyngeal lymphatic tissue hyperplasia is commonly seen in the persistent 
generalized lymphadenopathy (PGL) and AIDS related complex (ARC) stages of HIV 
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infection (Barzan, et al., 1990). In a study by Shahab, Osborne & Butler (1994), a review 
of the histology of lymphoid tissue from either the nasopharynx or tonsil in HIV positive 
patients showed that all the tissue had some degree of reactive follicular hyperplasia. It has 
been believed that NLTH is a benign process however one case report showed that NLTH 
can transform into malignant lymphoma but predictors of this type of transformation are 
unknown (Kieserman & Stern, 1995). 
 
Malignant lesions of the nasopharynx include NHL, Hodgkin’s lymphoma, Burkitts 
lymphoma and KS. Kaposi sarcoma is by far the most common malignancy in the head and 
neck in patients with HIV infection (Mohammed, 2007). Its existence in the nasopharynx 
is uncommon and not well documented but one study indicated that 4.3% of KS was found 
in the nasopharynx (Yang, Hsu & Liu, et al., 2009). 
 
Kaposi sarcoma and NHL are both AIDS defining malignancies. Incidence rates of these 
cancers have decreased and success in treatment of these malignancies in the HIV 
population has improved over the years, and the biggest contributor seems to be the effects 
of highly active antiretroviral therapy (HAART) (Bower, Palmieri & Dhillon, 2006). 
HAART has also increased the life span of AIDS sufferers, and this has increased the 
number of non-AIDS defining malignancies and Human Papilloma Virus (HPV) associated 
tumours (Bower, et al., 2006; Mohammed, 2007). Clinicians are thus observing a changing 
spectrum of malignancies in HIV infection.
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2.10  OBSERVATIONS AND HYPOTHESIS 
 
There is no study to date in South Africa documenting the prevalence of nasopharyngeal 
neoplasms. Hence, the purpose of this study is to determine the tumour types that do occur 
more frequently in the South African setting and to try to determine those factors that may 
be influencing the pathologies. Anecdotally, the impressions gained by clinicians in 
Otorhinolaryngology over the past 10 years is that the majority of the patients seen with 
mass lesions in the nasopharynx are being diagnosed with benign conditions, especially 
that of lymphoid hyperplasia.  
 
The hypothesis of this study is thus based on the experienced clinicians’ observation that 
the incidence of benign tumours of the nasopharynx is far more prevalent then those that 
are malignant. 
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CHAPTER 3 
 
3. MATERIALS AND METHODS 
This chapter describes the study process, lists the inclusion and exclusion criteria of this 
study and concludes with the ethical considerations. 
 
3.1  STUDY LOCATION  
This study was conducted at the Charlotte Maxeke Johannesburg Academic Hospital.  
 
3.2  STUDY DESIGN 
This study is a retrospective clinical audit. 
 
3.3  STUDY PERIOD 
This retrospective study identified patients diagnosed with nasopharyngeal pathology from 
01/01/2003 to 31/12/2008.   
 
3.4  STUDY POPULATION  
All adult patients who may have underwent a biopsy of the nasopharynx in theatre, under 
general anaesthetic, were considered for this study. 
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3.5  INCLUSION CRITERIA 
• Patients over 18yrs of age 
• All patients that underwent a biopsy of the post nasal space or nasopharynx. 
 
 3.6  EXCLUSION CRITERIA 
• Patients under 18yrs of age. Children were excluded from this study to prevent 
lymphoid hyperplasia, a very common pathology in this age group from 
confounding the results. 
• Patients previously diagnosed and treated for pathology of the nasopharynx that 
require a re-biopsy following treatment. This will avoid duplication of patients and 
identify only newly diagnosed patients. 
 
3.7  DATA COLLECTION 
Patients for this study, clinical information & pathology reports were identified from three 
main data sources, which included the operating theatre surgical register, patients’ hospital 
files, and National Health Laboratory Service (NHLS) database. 
 
The Otorhinolaryngology operating theatre surgical register was used as the primary 
reference to identify patients. Names, hospital numbers, age and date of biopsy of any 
patient who may have had a post nasal space biopsy were recorded. The main key words 
used to identify possible subject were: Post nasal space (PNS) biopsy, evaluation under 
anaesthesia (EUA) of PNS, adenoidectomy, nasopharyngeal biopsy, panendoscopy, 
intranasal biopsy, biopsy of nasal mass, EUA nasal cavity, nose or nostril and 
polypectomy.   
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The hospital numbers and patient names were used to search the NHLS database to 
identify all patients that had a biopsy of the nasopharynx. The hospital files for these 
patients were requested from the records department and viewed to obtain the history of 
the presenting complaints, clinical findings, histology reports, HIV status, age and gender. 
In a few cases, the histology results and HIV results were not found in patients files, and 
these were traced using the patients hospital number and the NHLS data base. 
 
Data that was retrieved from patients’ files included the following: 
1. Patients age 
2. Gender 
3. Presenting complaints 
4. Clinical findings 
5. Histopathology result 
6. HIV result 
 
3.8  DATA ANAYLSIS 
Data from record reviews were coded and captured onto an Excel spreadsheet and 
transferred to a Statistica version 6 (STATA-6) programme for analysis by computer. Non 
parametric statistical methods were used as the data was predominantly non-normal with 
unequal variance. Values are reported as median and range (minimum and maximum). 
Mann-Whitney U test was used to determine differences between independent variables. 
Spearman’s rank correlation coefficient (rho) was used to determine the associations. Chi 
square test was used for comparison of 2 proportions, counts etc. A multiple regression 
model was used to find independent predictors of malignancy. 
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3.9  ETHICAL CONSIDERATIONS 
Permission to conduct this study was obtained from the Acting Chief Executive Officer of 
CMJAH, Dr S Mfenyana and the Head of the School of Pathology of NHLS, Professor M 
Hale. 
 
Ethics clearance was granted by the University of Witwatersrand Human Research Ethics 
Committee to conduct this study. 
 
Informed consent from patients used in this study was not required since this is a 
retrospective clinical audit. The HIV testing that was carried out on some of these patients 
was done at the discretion of the doctor evaluating the patient and not for the purposes of 
this study. Routinely informed consent and pre-test counselling is required prior to testing 
for HIV. Patients are also adequately informed about the risks of surgical procedures prior 
to signing of a consent form.  
 
Confidentiality was maintained by keeping patients details anonymous, but traceable by 
using a coded number. 
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CHAPTER 4 
 
4.  RESULTS 
This chapter highlights the major findings of this study. Following the descriptive data of 
the study group, the data is then described in relation to the aims of this study.  
 
There were a total of 81 patients included in the study. This included 54 males (67%) and 
27 females (33%).  
 
The median age for the entire study group was 42 years. The male group had median age 
of 43.5 years while the female median age was lower at 39 years (see table 6). There was 
no statistical difference between the 2 genders in terms of their ages (Mann Whitney U 
test, p= 0.39- see Figure 10). 
 
Table 6: Age distribution of study patients (n=81) 
 Median Age Minimum Maximum 
Entire group 42years 18 years 82 years 
Males 43.5 years 18 years 76 years 
Females 39 years 19 years 82 years 
 
Patients were categorized into age groups (see figure 11) to determine if there was a trend 
for benign and malignant disease. There was no statistical difference between age and 
benign and malignant disease (p=0.14) or age groups and benign and malignant disease 
(p= 0.1) using Spearmans rank order correlations.  
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Figure 10: Box and whisker plot of age (yrs) vs. gender, 1=Male and 2=Female 
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Figure 11: Distribution of age groups (yrs) in the study population (n=81) 
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The main aim of this study was to determine the frequency of the various nasopharyngeal 
tumours. Fifty two patients (64%) had benign disease and 29 patients (36%) had malignant 
disease (see figure 12). Of the benign conditions, reactive lymphoid hyperplasia was found 
to be the most common, followed by inflamed respiratory mucosa. (See figure 13 for 
distribution all pathology and figure 14 for distribution and percentages of benign disease.) 
 
In the malignant group, NPC and NHL predominated. (See figure 15 for distribution and 
percentages of malignant disease.)  
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Figure 12: Distribution of benign and malignant disease (n=81) 
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Figure 13: Frequency of all nasopharyngeal pathology (n=81) 
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Figure 14: Frequency of benign disease (n=52) 
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Figure 15: Frequency of malignant disease (n=29) 
 
Thirty four males (65%) had benign disease compared to 18 females (35%) who had 
benign disease. Twenty males had malignant disease compared to 9 females (see table 7). 
There was no significant correlation between gender and malignancy (r= -0.04, p=0.75). 
 
Table 7: Distribution of males and females with benign and malignant disease 
 Males %Male Female %Female Total 
Benign  34 65% 18 35% 52 
Malignant 20 69% 9 31% 29 
 
Human immune deficiency virus (HIV) status was known in 41 of the 81 patients. The 
remaining 40 patients did not have a documented HIV result at the time of the study. 
Twenty eight patients were HIV positive and 13 patients were HIV negative. Of the 41 
patients whose HIV status was known, 25 were male and 16 were female. There was no 
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significant difference between the number of males with an unknown HIV status compared 
to the number of females with an unknown HIV status (X2 = 1.21, p = 0.27). (See table 8.)  
 
Table 8: Gender distribution among patients with HIV status known and those with 
unknown HIV status 
 HIV status known HIV status unknown 
Male 25(71%) 29 (73%) 
Female 16 (29%) 11 (27%) 
Total 41 40 
 
Nineteen (19) males (76% of all males) were HIV positive compared to 9 females (56% of 
all females) (see table 9). There was no significant difference between the number male 
HIV positive patients and female HIV positive patients (X2 = 1.98, p = 0.16)  
 
Table 9: HIV frequency among male and female study patients (n=41) 
Gender HIV 
positive 
%HIV 
positive 
HIV 
negative 
% HIV 
negative 
Total 
number 
Male 19 patients 76% 6 patients 24% 25 patients 
Female 9 patients 56% 7 patients 44% 16 patients 
 
The secondary aim of this study was to determine if there was an association between the 
presenting symptoms of nasopharyngeal disease and a tumour type (i.e. benign or 
malignant). Symptoms that were looked at specifically as symptoms of nasopharyngeal 
disease included: persistent nasal obstruction, epistaxis, hearing loss, otalgia, a neck mass 
and neurological fallout. Symptoms that made up the group labeled as “other” were non-
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specific for nasopharyngeal disease and were grouped together because of the low 
numbers. These symptoms included tinnitus, throat pain, trismus, dysphagia, odynophagia, 
snoring, anosmia, rhinitis, headache, parotid swelling, eye mass and hoarseness. Symptoms 
were recorded as present if the patient reported it as one of their presenting complaints or if 
the physician asked for or examined for that symptom. Symptoms were recorded as being 
absent if the information was not reported by the patient, never evaluated by the physician 
or not present. (See table 10). 
 
Table 10: Record of symptoms among the study patients 
Symptoms Present 
Nasal congestion 42 (52%) 
“Other” symptoms 27 (33%) 
Hearing loss 26 (32%) 
Neck mass 26 (32%) 
Epistaxis 12 (15%) 
Neurological 11 (14%) 
Otalgia 7 (9%) 
 
Using multiple regressions, a model was developed to predict tumour nature. Included in 
the model were age, gender, HIV status and the presence or absence of relevant symptoms 
listed in table 11 below. The independent predictors of tumour nature were: nasal 
congestion, epistaxis, hearing loss, otalgia and HIV status. The statistically significant 
positive predictors of malignancy were the presence of nasal congestion, epistaxis and 
otalgia.  
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The presence of hearing loss and a positive HIV status was independently associated with 
benign disease (see table 12). 
 
Table 11: Differences between malignant and benign disease with reference to 
common symptoms using a multiple regression model 
Number Symptoms Benign Malignant p value* 
1a Nasal congestion 24 (46%) 18 (62%)  
1b No Nasal  congestion 28 (54%) 11 (38%) 0.045* 
2a Epistaxis 5 (10%) 7 (24%)  
2b No Epistaxis 47 (90%) 22 (75%) 0.005* 
3a Hearing loss 19 (37%) 7 (24%)  
3b No Hearing loss 33 (63%) 22 (76%) 0.031* 
4a Otalgia 3 (6%) 4 (14%)  
4b No Otalgia 49 (94%) 25 (86) 0.036* 
5a Neck mass 15 (29%) 11 (38%)  
5b No Neck mass 37 (71%) 18 (62%) 0.33 
6a Neurological 3 (6%) 8 (27%)  
6b No Neurological 49 (94%) 21 (72%) 0.27 
7a “Other” symptoms 15 (29%) 12 (41%)  
7b No” Other” symptoms 37 (71%) 17 (59) 0.28 
* Indicates a statistically significant difference. Actual number of patients with complaints 
indicated in columns. Percentages indicated in parenthesis 
 
 
 
 44
Table 12: The frequencies of HIV positive status and HIV negative status among 
patients with benign and malignant disease 
 Benign disease Malignant disease P value 
HIV positive status 20 (80%) 8 (50%)  
HIV negative status 5 (20%) 8 (50%) 0.000* 
Total 25 16  
* P value determined from multiple regression model.  
 
The third aim of this study was to determine if there was an association between a tumour 
type and the presence of HIV infection. As mentioned above, the presence of HIV 
infection was associated with benign disease. In the subgroup of this study where HIV 
status was known, further analyses were carried out. There were a total of 41 patients in the 
group where the HIV status was known. Twenty eight patients (68.3%) were known 
positive. Spearman’s rank order correlations showed that there was no statistically 
significant correlation between age (p=0.53) or age groups (p=0.42) and HIV. 
 
The most common pathology in the HIV positive group was reactive lymphoid hyperplasia 
(57.2%), followed by NHL and KS. (See figure 16). 
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Figure 16: Frequency of pathology in the HIV positive group (n=28) 
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Figure 17: Frequency of pathology in the HIV negative group (n=13) 
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As previously mentioned the presence of persistent nasal blockage, epistaxis and otalgia 
were independent predictors of malignant disease. The presence of at least one or more of 
these symptoms was associated with an odds ratio of 3.06 for malignant disease. The 95% 
confidence intervals are 1.17 to 8.01. The risk attributable to these symptoms is 52%. (See 
table 13). 
 
The absence of HIV infection was in fact associated with malignant disease, with an odds 
ratio of 4.00 and 95% confidence intervals of 1.04 to 15.43. Alternatively it can be stated 
that the presence of HIV infection was in fact associated with benign disease with an odds 
ratio of 0.25 for malignant disease (i.e. protective) and 95% confidence intervals of 0.06 to 
0.96. (See table 13.) 
 
Table 13: Table of risk for malignant disease 
Risk of Malignant disease Presence of symptoms* HIV negative status 
(absence of HIV infection) 
Absolute risk 62% 47% 
Relative risk 2.15 2.1 
Risk difference 33% 24% 
Attributable risk 52% 54% 
Odds ratio 3.06 (1.17 – 8.01)# 4.0 (1.04 - 15.4)# 
* Symptoms include persistent nasal blockage, epistaxis, otalgia or more than 1 of them.  
# Ninety five percent (95%) confidence intervals in parenthesis. 
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CHAPTER 5 
 
5. DISCUSSION 
This chapter discusses the study findings and compares it to the findings in other relevant 
studies. The limitations of this study are also discussed at the end of this chapter.  
 
In this study, the nasopharyngeal biopsies of 81 adult patients presenting to CMJAH 
between 2003 and 2008, were analysed.  
 
The hypothesis of this study stated that benign tumours of the nasopharynx were more 
common than their malignant counterpart and the main aim was to identify the most 
common types of tumours. The results confirms this study’s hypothesis that benign 
conditions are more common (ratio of 1.8:1) with 64% of this study group having benign 
disease and 36% having malignant disease. It was unfortunately not possible to calculate 
the incidence or prevalence rates for the various pathologies because the total number of 
patients seen at the OPD during 2003 and 2008 were not recorded.   
 
A similar study was conducted over a seven year period in Uttar Pradesh in India, with the 
main aim being to determine the incidence rates of non-neoplastic and neoplastic polypoid 
lesions of the nasal cavity, paranasal sinuses and the nasopharynx. Although the overall 
observation showed that benign lesions in the three abovementioned sites outnumbered 
malignant lesions by a ratio of 1.5:1, no non-neoplastic lesions were found in the 
nasopharynx (Zafar, Khan & Afroz, et al., 2008). The histopathologies of the masses found 
in the nasopharynx were not covered in the article, thus a comparison to this study could 
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not be undertaken. The study by Zafar et al. (2008) also included biopsies of both adult and 
children (mean age of 22.5 years) whereas this study excluded patients under the age of 18 
years.  
 
In Biswas, Ghosh & Mukhopadhyay, et al. (2002), 30 cases of nasopharyngeal masses 
were reported in one year at their institution and this number accounted for 0.08% of all 
patients seen at their clinic in the same year. In their study, benign tumours were also more 
common than malignant disease with a ratio of 1.5:1 (as compared to 1.8:1 in this study). 
Antro-choanal polyp was found to be the most common pathology in their study, followed 
by angiofibroma and adenoids (or lymphoid hyperplasia). Nasopharyngeal Carcinoma 
accounted for 13% of the masses. The study by Biswas et al (2002), like the study by Zafar 
et al. (2008) included children with nasopharyngeal masses  
 
Adenoidal hypertrophy is very common in children and it usually regresses as they enter 
adulthood. In both of the abovementioned studies one would have expected the results to 
show a higher percentage of adenoids and a higher ratio of benign to malignant disease. 
The primary reason for excluding patients under the age of 18 years from this study was to 
avoid this common benign disease from confounding the results. 
 
In Johannsson, et al. (1997), malignant nasopharyngeal pathologies were evaluated in 
Iceland over a 26 year period.  Nasopharyngeal Carcinoma was found to be the most 
common malignant disease (82%), followed by plasmacytoma (4%), lymphoma (3%) and 
rhabdomyosarcoma (1%). This study also found that nasopharyngeal carcinoma to be the 
most common malignant disease (38% of all malignant disease and 13.6% of all 
nasopharyngeal disease), followed by NHL and KS (34.5% and 10.3% of all malignant 
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disease respectively). South Africa has poor record of the incidence of NPC and most 
studies assume its incidence to be similar to that of the Western world but this may not 
actually be true. An evaluation of true incidence rates of NPC in this country should rectify 
any discrepancies.  
 
In Hopping, et al. (1983), NPC was also found to be the most common malignancy 
followed by lymphoma which is in keeping with the findings of this study. The common 
benign conditions included chronic inflammation, lymphoid hyperplasia, Thornwaldt cyst, 
mucus retention cyst, choanal polyp and normal mucosa. Of note in this study, is that 
reactive lymphoid hyperplasia accounted for 62% of all benign disease and 39.5% of all 
nasopharyngeal masses.  
 
The secondary aim of this study was to determine if there was an association between 
symptoms and benign or malignant disease. This study found a statistically significant 
association between the symptoms of nasal obstruction, otalgia and epistaxis with 
malignancy. HIV positive disease and hearing loss was associated with benign disease. The 
presence of neck mass or neurological fallout was not found to be statistically significant. 
 
A study looking at nasopharyngeal masses and serous otitis media (Glynn, et al., 2006), 
found that all their patients with malignancy presented with hearing loss as their presenting 
complaint and were also found to have a suspicious looking mass in the nasopharynx. 
Masses were considered as being suspicious if they looked irregular, granular or exophytic. 
Three of their four patients demonstrating malignant lesions had unilateral otitis media 
effusions and one had bilateral effusions. This study being a retrospective record review 
did not record the clinicians’ assessment of the middle ear and the appearance of the 
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nasopharyngeal mass prior to biopsy, so correlation with other studies comparing the 
abovementioned findings was not possible. Contrary to their study results, hearing loss in 
this study was predictive for benign disease.  
 
In Stern, et al. (1990), a small series of 7 patients who presented with hearing loss and 
nasal obstruction were studied. They found all of the biopsies of the PNS to be that of 
benign lymphoid proliferation or hyperplasia and all patients in this group were HIV 
positive. Similar to this study, hearing loss was associated with benign disease. However 
this study found nasal obstruction to be associated with malignant disease (p=0.045). 
 
Hearing loss can be conductive, sensorineural or a mixed pattern. None of the studies, 
including this study, concentrated on the type of hearing loss that was present. A 
prospective study with larger numbers of patients may help determine exactly how hearing 
loss relates to nasopharyngeal pathology. 
 
In this study benign disease predominated and the major contributor of benign pathology 
was reactive lymphoid hyperplasia which was far more common in the HIV positive 
subset. Patients with HIV infection have a weaker immune system as compared to the 
general population and prolonged ear infections, presence of ototoxins released by the 
pathogens, systemic illnesses and ototoxic drugs (anti tuberculosis drugs and ARV’s) can 
contribute to hearing loss. This could possibly be the reason why this study found an 
association between hearing loss and benign disease rather than malignant disease.  
 
In Hopping, et al. (1983), the symptomatology of nasopharyngeal masses in adults was 
reviewed and it was determined that symptoms were more common in the malignant 
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group. Serous otitis media was the most common presenting symptom in both groups. 
Epistaxis and trismus was exclusive to the malignant group and malignant lesions 
presented with serous otitis media effusions as the earliest sign, followed by nasal 
obstruction, pain and bleeding. Although in this study, epistaxis, nasal obstruction and 
otalgia were associated with malignant disease, these symptoms were not exclusive to the 
malignant group. 
 
Cervical lymphadenopathy in the study by Hopping, et al. (1983) was present in both 
groups, but more commonly in the malignant group. Masses in the neck in the benign 
group were mostly from a malignant process not related to the nasopharynx.  
 
The lack of statistical significance in the presence of a neck mass and malignant disease in 
this study may be explained by a two main possibilities. Firstly, like Hopping, et al. (1983) 
neck masses were from malignancy not related to the nasopharynx. A few of the subjects 
in this study with malignant neck masses had a biopsy of their nasopharynx as part of a 
panendoscopy, which was aimed to find the primary site of malignancy, and none of these 
patients were found to have malignancy in the nasopharynx, thus skewing the results.  
 
Secondly, 34.6% of the study group had confirmed HIV positive results. In the HIV 
positive group, 71.4% had benign disease of the nasopharynx. In the presence of HIV 
infection, generalized lymphadenopathy is very common, especially in the PGL phase, and 
neck lymphadenopathy in this group is most likely to be associated with the HIV infection 
rather than nasopharyngeal disease. 
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Neurological fallout is generally associated with a malignant process. However, in this 
study the correlation of neurology with malignant disease was unsuccessful. Similarly as 
discussed above, looking for the primary site of malignancy in the nasopharynx for occult 
primary tumours, may during a panendoscopy reveal a benign process in the nasopharynx. 
Three of the 11 patients that had neurological symptoms in this study, had facial weakness. 
Nasopharyngeal malignancy needs to be very advanced to cause facial weakness and other 
cranial nerve palsies precede that of the facial nerve. These patients could possibly have 
had a Bell’s palsy. Also only 11 patients in the entire study group had neurological fallout 
and possibly larger numbers are needed to prove statistical significance. 
 
The third aim of this study was to determine if there was a relationship between 
nasopharyngeal neoplasms and a superimposed HIV infection. This study found that HIV 
infection was associated with benign disease and protective of malignant disease with an 
odds ratio of 0.25 (CI 0.06-0.96) for malignancy. Reactive lymphoid hyperplasia was 
predominant in the HIV positive group accounting for 57% of all the pathology. AIDS 
defining NHL and Kaposi sarcoma accounted for 17.9% and 10.7% of nasopharyngeal 
pathology respectively. 
 
Reports of nasopharyngeal lymphoid tissue hypertrophy are becoming more common in 
the literature. Probably one of the earliest is that of Stern, et al. (1990), who found all of 
their HIV positive patients having benign lymphoid proliferation accounting for their 
nasopharyngeal masses. All patients in their study group also complained of hearing loss. 
Based on these observations, it is suggested that nasal obstruction secondary to 
nasopharyngeal lymphoid proliferation together with hearing loss can be the first clues that 
a patient may have HIV infection.   
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A comparative study involving a much larger group compared nasopharyngeal biopsies of 
59 HIV positive patients to a control group of 218 HIV negative patients. It demonstrated, 
like this study, a significantly higher incidence of nasopharyngeal lymphoid hyperplasia in 
the HIV positive group. NLTH was also found to be more common in PGL and ARC 
stages of HIV infection. All of these masses morphologically were symmetrical and non-
ulcerated. (Barzan, et al., 1990). 
 
Evaluation of HIV infected patients with nasopharyngeal or tonsillar masses by Shahab, et 
al. (1994) revealed reactive follicular hyperplasia in all cases. All of these patients had 
nasal stuffiness as their presenting complaint. Cervical lymphadenopathy was present in 6 
of the 9 patients and hearing loss in 5 of the 9 patients.  
 
Non Hodgkin’s lymphoma is 60-200 times more common in HIV positive population 
(Bower, et al., 2006; Mohammed, 2007) and is an AIDS defining illness. Hodgkin’s 
lymphoma, on the other hand, is considered as non-AIDS defining but occurs 8-10 times 
more frequently in HIV positive population (Grogg, Miller & Dogan, 2007; Mohammed, 
2007). In this study, there were no cases of Hodgkin’s lymphoma but NHL accounted for 
17.9% of disease in the HIV positive subset and 7.7% in the known HIV negative group 
(2.3 times more common in the HIV positive group). 
 
Kaposi sarcoma is the most common HIV associated malignancy occurring between 1000-
77000 times more than the general population (Mohammed, 2007). The incidence rates of 
KS have gradually declined even in the pre- HAART era and this intensified with the 
introduction of HAART (Bower, et al., 2006; Mohammed, 2007). Kaposi sarcoma in the 
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nasopharynx is rare and incidence rates of KS in the nasopharynx are not well documented 
in the literature however one study quotes a rate of 4.3% (Yang, et al., 2009). In this study 
KS was present in 3 out of 81 patients, comprising of 10.3% of all malignant 
nasopharyngeal pathology and was also found to exist exclusively in HIV positive patients. 
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5.1 LIMITATIONS 
Although this study was very informative, there were a few limitations that are discussed 
below. 
 
The adequacy of the records, particularly the clinical information captured on the 
admission notes, was sub-standard. Clinicians were all not fully aware of all the 
symptomatology of nasopharyngeal pathology so history taking and examination in most 
instances were not complete and consistent but were adequate to complete this study. The 
best way to overcome such a problem is to conduct a prospective study, thus ensuring all 
subjects undergo a standardized evaluation. 
 
Clinic records prior to 2006 were poor. The total number of patients attending the OPD 
during the study period could not be determined thus incidence and prevalence rates could 
not be determined. 
 
A small number of archived hospital records were also misfiled and some clinical 
information was misplaced. The number in this instance was negligible and clinical notes 
were carefully scrutinized to ensure that the recorded data was actually that of the subject 
in question. 
 
The theatre log book which was the first source of screening for patients for this study had 
a negligible amount of patients’ details that were incorrectly captured. This made clinical 
records difficult to trace and a few patients were thus not considered for this study. 
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Charlotte Maxeke Johannesburg Academic Hospital is a tertiary-quaternary centre for 
referral of patients to specialised units such as radiation oncology and medical oncology. 
The actual numbers of malignant nasopharyngeal tumours may be much higher than that 
determined in this study as patients may have had a direct referral to these units rather than 
being evaluated or biopsied by the Otorhinolaryngology unit at CMJAH.  
 
Although this study is a six year review it only produced 81 patients that met inclusion 
criteria. Perhaps a longer study period is needed to get better results but a prospective study 
will give a more accurate and detailed account of the tumours. 
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CHAPTER 6 
 
6. CONCLUSIONS AND RECOMMENDATIONS 
Benign disease of the nasopharynx is much more common than malignant pathology. 
Symptoms of otalgia, nasal obstruction and epistaxis appear to be associated with 
malignant disease. Hearing loss and HIV infection were found to be predictors of benign 
disease. 
 
Although a prevalence rate of NPC could not be determined in this study, NPC is still the 
most common malignant disease of the nasopharynx. Reactive lymphoid hyperplasia was 
shown to be the most common benign disease. Most of the patients that had reactive 
lymphoid hyperplasia had concurrent HIV infection. 
 
Symptoms and macroscopic appearance of masses in the nasopharynx could guide one as 
to whether or not a nasopharyngeal mass is benign or malignant and whether it warrants a 
biopsy. However, if one opts not to biopsy a benign looking nasopharyngeal lesion, close 
and regular follow up is recommended. The follow up examination should include nasal 
endoscopy in the OPD setting and regular CT scanning of the nasopharynx to look for 
progression of the lesion and to look for asymmetry especially in the pharyngeal recess. 
 
This conservative approach to nasopharyngeal masses should be reserved for institutions 
that have very limited financial and surgical resources. This “watch and see” approach may 
also be of value in institutions that have a very high incidence of HIV infection, where one 
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can predict that most patients will have a nasopharyngeal mass, and it is most likely to be a 
benign process. Biopsy should then be performed for all suspicious looking lesions. 
 
With emerging case reports of malignant transformation of NLTH, one perhaps should 
have a higher threshold for biopsying even benign looking lesions. 
 
Nasal obstruction is one of the most common presentations of nasopharyngeal disease; 
hence it would be both beneficial to the patient and the physician to surgically relieve the 
obstruction by way of adenoidectomy if it is safe to do so and if there is no progression of 
disease intracranially. This way the patient would benefit by having a good airway to 
breathe through and the surgeon can have the specimen evaluated histologically for 
malignancies. 
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APPENDIX A 
 
Filtered data of study patients (n=81) 
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
A E F G H I J K L M N O P S T U V
No Gender Age Age Group Persistent nasal blockage Epistaxis Hearing loss Otalgia Neck mass Neurological fallout Other HIV Presenting Symptoms Benign or Malignant Histo group Key
1 1 42 3 1 1 2 1 1 1 Hearing loss 1 Inflamed respiratory mucosa Gender
2 1 52 4 2 2 1 2 1 1 Epistaxis, Nasal obstruction & otalgia 1 Reactive lymphoid hyperplasia Male 1
3 2 30 1 1 1 2 2 1 1 2 Hearing loss, otalgia &throat pain 2 Nasopharyngeal carcinoma Female 2
4 1 76 5 1 1 2 1 2 1 2 Neck Mass, hearing loss & tinnitus 2 Non Hodgkins Lymphoma
5 2 37 2 2 1 1 2 2 1 2 Nasal obstruction, Otalgia, neck mass 2 Non Hodgkins Lymphoma HIV Status
6 1 60 4 1 1 1 1 2 1 Neck Mass 1 Benign respiratory epithelium HIV Negative 1
7 1 34 2 2 2 1 1 1 1 2 Nasal obstruction, epistaxis & throat pain 1 Inflamed respiratory mucosa HIV Positive 2
8 1 47 3 2 2 1 1 1 1 Nasal mass, nasal obstruction, epistaxis 2 Nasopharyngeal carcinoma
9 1 36 2 2 1 1 1 2 1 Nasal obstruction, nasal discharge & neck mass 2 Nasopharyngeal carcinoma Tumour Group
10 1 41 3 2 1 2 1 1 1 2 Nasal obstruction & Hearing loss 1 Reactive lymphoid hyperplasia Benign 1
13 1 46 3 2 2 2 1 1 1 Hearing loss, nasal obstruction & epistaxis 1 Reactive lymphoid hyperplasia Malignant 2
14 1 75 5 1 1 2 1 1 1 2 Hearing loss & Rt Tinnitus 1 Reactive lymphoid hyperplasia
15 2 35 2 2 1 1 1 1 1 2 Nasal obstruction 1 Reactive lymphoid hyperplasia Symptom
17 1 28 1 1 1 1 1 2 1 2 Neck Mass 1 Inflamed respiratory mucosa Negative or not asked for on history 1
18 1 43 3 1 1 2 1 1 1 2 Hearing loss, tinnitus & snoring 1 Reactive lymphoid hyperplasia Symptom present 2
19 2 33 2 1 1 1 1 1 1 2 Trismus & TMJ pain 1 Reactive lymphoid hyperplasia
21 2 32 2 2 1 1 1 1 1 2 Nasal obstruction 1 Reactive lymphoid hyperplasia Age group
25 2 39 2 1 1 1 1 1 1 2 1 Chronic throat pain 1 Reactive lymphoid hyperplasia 18-30 1
26 1 18 1 2 2 1 1 1 1 Epistaxis,Nasal mass with obstruction 1 Reactive lymphoid hyperplasia 31-40 2
27 1 35 2 2 1 2 2 1 2 2 2 Nasal obstruction, otalgia, hearing loss & anosmia 2 Kaposi Sarcoma 41-50 3
28 1 25 1 2 2 1 1 2 1 Nasal obstruction,Epistaxis, Neck mass 2 Nasopharyngeal carcinoma 51-60 4
29 2 41 3 2 1 1 1 1 2 Nasal obstruction, facial pain 2 Non Hodgkins Lymphoma >60 5
30 2 28 1 2 2 1 1 1 1 2 Epistaxis & nasal obstruction 2 Kaposi Sarcoma
31 1 31 2 2 1 1 1 1 1 Nasal obstruction 1 Reactive lymphoid hyperplasia
32 1 58 4 2 1 2 1 1 1 1 Nasal obstruction & Hearing loss 1 Squamous papilloma
33 1 55 4 2 1 1 1 1 1 2 2 Nasal obstruction & dysphagia 2 Non Hodgkins Lymphoma
34 1 41 3 2 1 1 1 1 1 2 Nasal obstruction 2 Plasmablastic lymphoma
35 2 51 4 2 1 1 1 1 1 2 Nasal obstruction 1 Reactive lymphoid hyperplasia
36 1 40 2 2 1 2 1 1 1 2 Nasal obstruction & Hearing loss 1 Reactive lymphoid hyperplasia
37 1 52 4 2 1 2 1 1 1 Nasal obstruction & Hearing loss 1 Benign respiratory epithelium
40 1 41 3 2 2 1 1 1 1 2 2 Nasal mass, epistaxis & dysphagia 2 Kaposi Sarcoma
41 1 48 3 1 1 2 1 2 1 Neck Mass & blocked ear 2 Nasopharyngeal carcinoma
42 2 44 3 2 1 1 1 1 1 1 Nasal obstruction 1 Reactive lymphoid hyperplasia
43 2 35 2 2 1 1 1 1 1 2 Nasal obstruction 1 Reactive lymphoid hyperplasia
44 1 69 5 1 1 2 1 1 1 Hearing loss 1 Inflamed respiratory mucosa
45 2 52 4 2 2 1 1 1 1 2 Nasal obstruction &epistaxis 1 Reactive lymphoid hyperplasia
46 2 59 4 1 1 2 1 1 1 1 Hearing loss 1 Reactive lymphoid hyperplasia
47 1 25 1 1 1 1 1 1 2 2 1 Blindness & other CN fallout & dysphagia 2 Adenoid cystic carcinoma
48 2 30 1 2 1 1 1 2 1 Nasal obstruction & neck mass 1 Reactive lymphoid hyperplasia
49 1 76 5 2 2 1 1 1 1 Nasal obstruction &epistaxis 2 Plasmacytoma
50 1 32 2 2 1 2 1 1 1 2 Nasal obstruction & hearing loss 1 Reactive lymphoid hyperplasia
1A E F G H I J K L M N O P S T U V
No Gender Age Age Group Persistent nasal blockage Epistaxis Hearing loss Otalgia Neck mass Neurological fallout Other HIV Presenting Symptoms Benign or Malignant Histo group Key
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
51 1 34 2 2 1 2 1 1 1 2 2 Nasal obstruction, hearing loss & tinnitus 1 Reactive lymphoid hyperplasia Gender
54 2 67 5 1 1 1 1 1 1 2 Rhinitis 1 Inflamed respiratory mucosa Male 1
55 1 37 2 1 1 1 1 1 2 1 Cranial nerve palsies & headaches 2 Combined small cell neuroendocrine carcinoma & SCC Female 2
56 1 65 5 2 1 1 1 1 2 Nasal obstruction & neurological fallout 2 Nasopharyngeal carcinoma
57 2 19 1 1 1 1 1 2 1 1 Neck Mass 2 Nasopharyngeal carcinoma HIV Status
58 2 21 1 1 2 2 1 2 1 1 Neck mass, epistaxsis & hearing loss 2 Nasopharyngeal carcinoma HIV Negative 1
60 2 26 1 2 1 2 1 1 1 2 Nasal obstruction, anosmia & hearing loss 1 Reactive lymphoid hyperplasia HIV Positive 2
61 1 56 4 2 1 2 1 2 1 Neck mass, nasal obstruction & hearing loss 2 Spindled & epithelioid cell neoplasm 
62 1 45 3 2 1 1 1 1 1 2 2 Nasal obstruction, dysphagia & odynophagia 2 Non Hodgkins Lymphoma Tumour Group
63 1 50 3 2 1 2 1 1 1 2 2 Nasal obstruction,hearing loss & tinnitus 1 Reactive lymphoid hyperplasia Benign 1
64 1 35 2 1 1 2 1 1 2 2 1 Facial pain, headache, hearing loss & ophthalmoplegia 2 Nasopharyngeal carcinoma Malignant 2
65 1 42 3 2 1 2 2 1 1 2 Nasal obstruction, Hearing loss & otalgia 1 Reactive lymphoid hyperplasia
66 1 67 5 1 1 2 1 1 1 2 Hearing loss 1 Reactive lymphoid hyperplasia Symptom
67 2 41 3 2 1 1 1 1 1 2 Nasal obstruction 1 Reactive lymphoid hyperplasia Negative or not asked for on history 1
69 1 51 4 2 1 1 1 2 1 1 Nasal obstruction & neck nodes 2 Non Hodgkins Lymphoma Symptom present 2
70 1 39 2 1 1 1 1 2 1 2 2 Parotid swelling & neck nodes 1 Inflamed respiratory mucosa
71 1 61 5 1 1 1 1 2 1 Neck Mass 1 Benign respiratory epithelium Age group
72 1 44 3 1 1 1 1 1 1 2 2 Hoarseness- sq ca of vc 1 Reactive lymphoid hyperplasia 18-30 1
73 2 67 5 1 1 1 1 1 2 2 Eye mass, blindness & anosmia 2 Plasmacytoma 31-40 2
74 2 55 4 1 1 2 1 1 2 1 Hearing loss & facial palsy 1 Inflamed respiratory mucosa 41-50 3
77 1 20 1 2 1 1 1 2 1 1 Neck Mass & nasal blockage 2 Nasopharyngeal carcinoma 51-60 4
78 1 43 3 1 1 1 1 1 2 2 2 Headache , facial weakness & diplopia 1 Benign  Inflammatory polyp >60 5
79 2 28 1 1 1 1 2 1 1 2 1 Neck pain & otalgia 2 Nasopharyngeal carcinoma
80 1 35 2 2 1 1 1 1 1 Nasal obstruction 1 Inflamed respiratory mucosa
81 1 38 2 2 2 1 1 1 2 2 Diplopia, nasal obstruction & epistaxis 2 Non Hodgkins Lymphoma
82 1 25 1 1 1 1 1 1 2 2 Facial weakness & diplopia 1 Reactive lymphoid hyperplasia
83 1 28 1 2 1 1 1 2 1 2 Neck Mass, blocked nose &dysphagia 2 Non Hodgkins Lymphoma
84 2 82 5 1 1 1 1 1 1 2 Sore throat 1 Reactive lymphoid hyperplasia
85 1 58 4 1 1 1 1 2 1 Neck mass 1 Benign respiratory epithelium
86 1 63 5 1 1 1 1 2 1 Neck mass 1 Inflamed respiratory mucosa
87 1 35 2 1 1 2 1 2 1 Neck mass & hearing loss 1 Reactive lymphoid hyperplasia
88 2 74 5 1 1 1 1 1 1 2 Sore throat 2 Non Hodgkins Lymphoma
89 1 63 5 1 1 1 1 2 1 Neck mass 1 Benign respiratory epithelium
91 1 71 5 1 1 1 1 2 1 Neck Mass 1 Inflamed respiratory mucosa
92 1 47 3 1 1 1 1 2 1 2 2 Neck Mass, dysphagia & difficulty breathing 1 Benign  Inflammatory polyp
93 2 78 5 1 1 1 1 2 1 Neck Mass 1 Reactive lymphoid hyperplasia
94 1 60 4 1 1 1 1 2 1 Immature squamous metaplasia 1 Immature squamous metaplasia
95 2 33 2 2 1 2 2 1 1 2 Nasal obstruction, Hearing loss & otalgia 1 Reactive lymphoid hyperplasia
96 2 58 4 1 1 1 1 2 1 2 Neck mass & dysphagia 1 Benign respiratory epithelium
97 1 47 3 1 1 1 1 2 1 Neck mass 1 Reactive lymphoid hyperplasia
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